How to get insurance to cover semaglutide (2026 prior-authorization guide)
Coverage comes down to matching an approved indication and clearing the prior authorization. The paths that get approved, how to win the PA, and when to pay cash instead.
Why semaglutide coverage is so inconsistent
Semaglutide's list price is high — brand Wegovy runs near $1,349/month — and historically many insurers treated weight-loss drugs as optional, an easy basis for denial. That's shifting as the evidence matures, but coverage still depends heavily on which indication your prescriber documents and what your specific plan's formulary allows. The single most useful reframe: insurers pay for approved medical indications, so the game is matching your situation to one your plan covers, then clearing the paperwork.
The indication paths that get approved
Four paths account for most approvals. Cardiovascular risk: after the SELECT trial (a 20% reduction in major adverse cardiovascular events), Wegovy is approved to reduce heart-attack and stroke risk in adults with established cardiovascular disease and overweight or obesity — a strong, documentable basis. Type 2 diabetes: Ozempic and oral Rybelsus are widely covered for glycemic control. Obstructive sleep apnea: tirzepatide (Zepbound) carries an OSA indication some plans cover. Medicare Bridge: eligible beneficiaries get covered brand GLP-1s at $50/month starting July 2026. Weight loss alone is the weakest path and the most likely to require BMI-plus-comorbidity documentation.
How to win the prior authorization
A prior authorization is a form your prescriber submits arguing medical necessity. Approvals rise sharply when the request is complete and specific. The elements that matter: the qualifying diagnosis with the correct code; documented BMI (and the comorbidity if weight-based); a record of prior attempts at lifestyle change or other therapies where the plan requires "step therapy"; and, where applicable, a reference to the relevant trial evidence (SELECT for cardiovascular). Ask your prescriber to cite the specific approved indication rather than "weight loss," and to attach the supporting documentation up front rather than waiting for the plan to request it.
| Prior-authorization element | Why it matters |
|---|---|
| Correct diagnosis code | Matches an indication the plan covers |
| Documented BMI + comorbidity | Meets weight-based criteria |
| Step-therapy history | Shows prior attempts if required |
| Trial evidence (e.g., SELECT) | Strengthens medical-necessity argument |
If you're denied
A denial is often not the end. Plans must offer an internal appeal, and you can escalate to an external review if that fails. An effective appeal cites the plan's own coverage criteria, attaches the missing documentation, and — where relevant — references the trial evidence supporting the indication. Many initial denials are reversed on appeal simply because the first submission was incomplete. Your prescriber's office usually leads this, but you can request the plan's specific denial reason and coverage policy to target the appeal precisely.
When cash-pay is the smarter move
Sometimes chasing coverage costs more time and money than paying cash. If you don't have a qualifying indication, or your plan simply excludes weight-loss drugs, the math often favors a transparent cash-pay path: the new oral Wegovy at ~$149/month, or a flat-rate compounded program around $145/month, both of which can undercut an insured copay in some plans. For eligible Medicare beneficiaries, the $50 Bridge is almost always the cheapest route. The rational sequence: check whether an approved indication fits, pursue the prior authorization if it does, and fall back to a transparent cash-pay option if coverage is genuinely unavailable. Suitability and dosing remain clinical decisions for your prescriber.
Frequently asked questions
How do I get insurance to cover semaglutide?
Match an FDA-approved indication your plan covers — cardiovascular risk reduction (Wegovy, post-SELECT), type 2 diabetes (Ozempic/Rybelsus), or sleep apnea (tirzepatide) — then clear a prior authorization with the correct diagnosis code, documented BMI/comorbidity, and any step-therapy history. Coverage for weight loss alone is the hardest path.
Why won't my insurance cover Wegovy for weight loss?
Many plans treat weight-loss-only drugs as excluded or gate them behind BMI-plus-comorbidity criteria and prior authorization. Coverage is much more likely when tied to an approved indication like cardiovascular risk reduction or diabetes.
What should a semaglutide prior authorization include?
The qualifying diagnosis and code, documented BMI and any comorbidity, step-therapy history where required, and — where relevant — trial evidence such as SELECT for the cardiovascular indication. Complete, specific submissions are approved far more often.
What if my semaglutide claim is denied?
Request the plan's specific denial reason and coverage policy, then file an internal appeal (and external review if needed) that cites those criteria and attaches the missing documentation. Many initial denials are reversed because the first submission was incomplete.
Is it cheaper to pay cash than fight for coverage?
Sometimes. If you lack a qualifying indication, transparent cash-pay options like the oral Wegovy pill (~$149/month) or a flat-rate compounded program (~$145/month) can beat an insured copay. Eligible Medicare beneficiaries usually get the cheapest route via the $50 Bridge.
References
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes (SELECT). N Engl J Med. 2023.
- U.S. FDA. Wegovy prescribing information — cardiovascular indication.
- CMS / Medicare.gov. Medicare GLP-1 Bridge, 2026.
- WeightLoss GLP-1 methodology, July 2026.
Clinical and regulatory figures from published trials, FDA, and CMS communications; pricing from provider-advertised and manufacturer rates checked July 2026 and subject to change. Educational, not medical or financial advice.